Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319677 | 1.00 | ADRA2B (0.31) | ADRA2BHRH1DRD3ALDH1A1 | |
| SCHEMBL72326 | 1.00 | — | — | |
| SCHEMBL21508069 | 1.00 | ADRA2B (0.31) | ADRA2BHRH1DRD3ALDH1A1 | |
| SCHEMBL73462 | 0.97 | — | — | |
| SCHEMBL6353022 | 0.97 | — | — | |
| SCHEMBL27172 | 0.88 | — | — | |
| SCHEMBL3639333 | 0.88 | — | — | |
| SCHEMBL589516 | 0.78 | — | — | |
| SCHEMBL20523341 | 0.76 | — | — | |
| SCHEMBL7790096 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682506-B1 | DIPEPTIDE-ANALOGUE SYNTHESIS | BOEHRINGER INGELHEIM PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | claimed |
| US-7462438-B2 | Resist material and pattern formation method using the same | PANASONIC CORPORATION (JP) | 2008-12-09 | — | — | US | claimed |
| US-20060263719-A1 | Resist material and pattern formation method using the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. | 2006-11-23 | — | — | US | claimed |
| CN-1866129-A | Resist material and pattern formation method using the same | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2006-11-22 | — | — | CN | claimed |
| EP-1682506-A1 | DIPEPTIDE-ANALOGUE SYNTHESIS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | claimed |
| US-20050113572-A1 | Dipeptide synthesis | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2005044799-A1 | DIPEPTIDE-ANALOGUE SYNTHESIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | claimed |
| JP-2003529546-A | — | — | 2003-10-07 | — | — | JP | claimed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | claimed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1994024106-A1 | HERBICIDAL (4-SUBSTITUTED PYRIDYL)-3-CARBINOLS | ZENECA LIMITED (GB) | 1994-10-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ADRA2B 3528/4885HRH1 909/4885DRD3 4419/4885 |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ADRA2B 3670/4885HRH1 845/4885DRD3 4421/4885 |
| US-20050113572-A1 | Dipeptide synthesis | DNPEP, VIP, ASNS | ADRA2B 4758/4885HRH1 4165/4885DRD3 4204/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ADRA2B 3670/4885HRH1 845/4885DRD3 4421/4885 |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | NOS1, CTSK, CTSS | ADRA2B 2045/4885HRH1 994/4885DRD3 4092/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ADRA2B 3670/4885HRH1 845/4885DRD3 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.